Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3276169
Max Phase: Preclinical
Molecular Formula: C60H84N14O14
Molecular Weight: 1225.42
Molecule Type: Small molecule
Associated Items:
ID: ALA3276169
Max Phase: Preclinical
Molecular Formula: C60H84N14O14
Molecular Weight: 1225.42
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1c2oc3c(C)ccc(C(=O)N[C@H]4CNC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]5CCCN5C(=O)[C@@H](C(C)C)NC4=O)c3nc-2c(C(=O)N[C@H]2CNC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]3CCCN3C(=O)[C@@H](C(C)C)NC2=O)c(N)c1=O
Standard InChI: InChI=1S/C60H84N14O14/c1-27(2)42-59(86)73-21-15-17-36(73)57(84)69(11)25-38(75)71(13)46(29(5)6)55(82)62-23-34(52(79)67-42)64-51(78)33-20-19-31(9)49-44(33)66-45-40(41(61)48(77)32(10)50(45)88-49)54(81)65-35-24-63-56(83)47(30(7)8)72(14)39(76)26-70(12)58(85)37-18-16-22-74(37)60(87)43(28(3)4)68-53(35)80/h19-20,27-30,34-37,42-43,46-47H,15-18,21-26,61H2,1-14H3,(H,62,82)(H,63,83)(H,64,78)(H,65,81)(H,67,79)(H,68,80)/t34-,35-,36-,37-,42+,43+,46-,47-/m0/s1
Standard InChI Key: TVNRGJHZMXWHCK-RGXAGSLWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1225.42 | Molecular Weight (Monoisotopic): 1224.6291 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Moore S, Patel RP, Atherton E, Kondo M, Meienhofer J.. (1976) Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1., 19 (6): [PMID:950643] [10.1021/jm00228a006] |
Source(1):